Press Release November 16, 2020

Lacerta Therapeutics Enters R&D Collaboration with UCB

The Life Sciences team advised Lacerta Therapeutics on its collaboration and licensing agreement with UCB.
Lacerta Therapeutics is a clinical-stage gene therapy company that is leveraging its proprietary adeno-associated virus (AAV) vector technology and manufacturing platforms to develop treatments for central nervous system and lysosomal storage diseases.
UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
The research collaboration and licensing agreement with UCB will focus on a central nervous system (CNS) disease with a high unmet need. Lacerta Therapeutics will lead research, preclinical activities and the early manufacturing process development, while UCB will complete IND-enabling studies, manufacturing and clinical development. 
The Goodwin team was led by Noelle Dubiansky and consisted of Emily Beman, with invaluable assistance from Kathryn Weston.
For more details, read the press release and articles in Endpoints, Fierce Biotech, and PharmaTimes